Trends in prescription and determinants of persistence to antihypertensive therapy: The papeete study

High Blood Pressure and Cardiovascular Prevention

Volumn 16, Issue 4, 2009, Pages 167-176

  Costa, Francesco Vittorio ^a   Esposti, Luca Degli ^b   Cerra, Carlo ^c   Veronesi, Chiara ^b   Buda, Stefano ^b  

^a Madre Fortunata Toniolo Hospital   (Italy)

^b Economics and Outcomes Research   (Italy)

^c ASL Pavia   (Italy)

Author keywords

Administrative databases; Angiotensin receptor blockers; Antihypertensive therapy; Drug utilization; Persistence to treatment; Predictors of non persistence

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN; TELMISARTAN; VALSARTAN;

ADULT; AGE; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; COHORT ANALYSIS; ECONOMIC ASPECT; FEMALE; GENDER; HUMAN; HYPERTENSION; ITALY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT DURATION; TREND STUDY;

EID: 76249098614     PISSN: 11209879     EISSN: 11791985     Source Type: Journal    
DOI: 10.2165/11530410-000000000-00000     Document Type: Article

References (33)

1. Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network metaanalysis. JAMA 2003; 289: 2534-2544
2. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure lowering regimens on major cardiovascular events: second cycle of prospectively designed overviews. Lancet 2003; 362: 1527-1535
3. Chalmers J. Comparison of various blood pressure lowering treatments on the primary prevention of cardiovascular outcomes in recent randomised clinical trials. Clin Exp Hypertens 2004; 26: 709-719
4. Turnbull F, Neal B, Ninomiya T, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. BMJ 2008; 336 (7653): 1121-1123
5. Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 European Countries, Canada, and the United States. JAMA 2003; 289 (18): 2363-2369
6. Kotseva K, Wood D, De Backer D, et al., for theEUROASPIRE Study Group. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009; 373: 929-940
7. Eni C, Okonofua EC, Simpson KN, et al. Therapeutic inertia is an impediment to achieving the Healthy People 2010. Blood Pressure Control Goals Hypertens 2006; 47: 345-351
8. Fujita T, Shimamoto K, Wu Z, et al. What are the major challenges in getting patients to the optimal BP goal? Difficulties in educating doctors and patients. Int J Clin Pract Suppl 2006; 150: 20-22
9. Costa FV. Compliance with antihypertensive treatment. Clin Exp Hypertens 1996 Apr-May; 18 (3-4): 463-472
10. Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. Am J Hypertens 2006; 19: 1190-1196
11. Lopatriello S, Berto P, Cramer J, et al. Different aspects of adherence to antihypertensive treatments [abstract]. Expert Rev Pharmacoeconomics Outcomes Res 2004; 4 (3): 317-333
12. Hyre AD, Krousel-Wood MA, Muntner P, et al. Prevalence and predictors of poor antihypertensive medication adherence in an urban health clinic setting. J Clin Hypertens (Greenwich) 2007 Mar; 9 (3): 179-186
13. Degli Esposti L, Degli Esposti E, ValpianiG, et al.Aretrospective, populationbased analysis of persistence with antihypertensive drug therapy in primary care practice in Italy. Clin Ther 2002 Aug; 24 (8): 1347-1357
14. Degli Esposti E, Sturani A, Di Martino M, et al. Long-term persistence with antihypertensive drugs in new patients. J Hum Hypertens 2002; 16: 439-444
15. Mazzaglia G, Mantovani L, Sturkenboom MC, et al. Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. J Hypertens 2005; 23: 2093-2100
16. Bourgault C, Senecal M, Brisson M, et al. Persistence and discontinuation patterns of antihypertensive therapy among newly treated patients: a population-based study. J Hum Hypertens 2005 Aug; 19 (8): 607-613
17. Corrao G, Zambon A, Parodi A, et al. Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. J Hypertens 2008 Apr; 26 (4): 819-824
18. Costa FV, D'Ausilio A, Bianchi C, et al. Adherence to anti-hypertensive medications: a review and update. High Blood Pressure Cardiovasc Prev 2009 Sep; 16 (3): 101-110
19. Catalan VS, LeLorier J. Predictors of long-term persistence on statins in a subsidized clinical population. Value Health 2000 Nov-Dec; 3 (6): 417-426
20. Elliott WJ, Plauschinat CA, Skrepnek GH, et al. Persistence, adherence, and risk of discontinuation associated with commonly prescribed antihypertensive drug monotherapies. J Am Board Fam Med 2007; 20: 72-80
21. Hasford J, Mimran A, Simons WR. A population-based European cohort study of persistence in newly diagnosed hypertensive patients. J Hum Hypertens 2002; 16: 569-575
22. Erkens JA, Panneman MM, Klungel OH, et al. Differences in antihypertensive drug persistence associated with drug class and gender: a PHARMO study. Pharmacoepidemiol Drug Saf 2005 Nov; 14 (11): 795-803
23. Haynes RB, McDonald HP, Garg AX. Helping patients follow prescribed treatment: clinical applications. JAMA 2002; 288: 2880-2883
24. Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004; 43: 10-17
25. Kettani FZ, Dragomir A, Côté R et al. Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention. Stroke 2009; 40: 213-220
26. Breekveldt-Postma NS, Penning-van Beest FJA, Siiskonen SJ, et al. The effect of discontinuation of antihypertensives on the risk of acute myocardial infarction and stroke. Curr Med Res Opin 2008; 24: 121-127
27. Sokol MC, McGuigan KA, Verbrugge RR, et al. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005; 43: 521-530
28. American Heart Association. High blood pressure 2009 [online]. Available from URL: http://www.americanheart.org/presenter.jhtml?identifier=2139 [Accessed 2009 Sep 15
29. Hansson L, Lloyd A, Anderson P, et al. Excess morbidity and cost of failure to achieve targets for blood pressure control in Europe. Blood Press 2002; 11 (1): 35-45
30. Gaziano TA, Bitton A, Anand S, et al. The global cost of non optimal blood pressure. J Hypertens 2009; 27: 1472-1477
31. Falaschetti E, Chaudhury M, Mindell J, et al. Continued improvement in hypertension management in England: results from the Health Survey for England 2006. Hypertension 2009; 53: 480-486
32. Theodoratou D, Maniadakis N, Fragoulakis V, et al. Analysis of published economic evaluations of angiotensin receptor blockers. Hellenic J Cardiol 2009; 50: 105-118
33. Poluzzi E, Strahinja P, Vargiu A, et al. Initial treatment of hypertension and adherence to therapy in general practice in Italy. Eur J Clin Pharmacol 2005; 61: 603-609